About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 

Biocon Moves Up to Rank No. 6 on Science Careers' Top 20 Global Pharma & Biotech Employers List 2019


Bengaluru, Karnataka, India, October 28, 2019:

Biocon Ltd, an innovation-led global biopharmaceuticals company, has moved up in the Top 10 Global Biotech Employers ranking for 2019 and continues to be the only Company from Asia to feature on the prestigious U.S.-based Science magazine’s annual ‘Science Careers Top 20 Employers’ list, since its debut in 2012. Ranked at No. 6 among global pharma and biotech companies in 2019, Biocon has moved up from No. 7 in 2018 and No. 9 in 2017. Biocon has been consistently recognized for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘leadership makes changes needed.’

The ranking is a result of the 2019 Science Careers Top Employers global survey conducted by the U.S.-based Science magazine to determine which companies in the biotech and pharmaceutical industry have the best reputations as employers globally. Biocon has consistently featured among the Top Ten Global Biotech players for several years, which is reflective of the entrepreneurial work culture that fosters innovation and a deep sense of purpose in the workforce at Biocon.

Kiran Mazumdar Shaw, CMD, Biocon said: “We are delighted to have moved up the ranks in this prestigious list of Top Global Biotech Employers. Our rank at No. 6 is an outcome of our commitment to create an inspiring workplace built on a strong foundation of innovation. The quality of our talent drawn from across the globe enables us to use cutting-edge science to develop high quality biopharmaceuticals with a potential to benefit a billion lives. We have consciously created a culture that encourages ideation, experimentation and collaboration to address unmet patient needs.”

Biocon was ahead of leading global pharma companies like Novozymes, Roche, Eli Lilly, Abbott, Novartis, Pfizer etc. in the 2019 rankings. The Top 5 global players in this year’s list are Alnylam, Regeneron, Incyte, Merck KGaA and Spark therapeutics.

Respondents to the web-based survey were asked to rate companies based on 23 characteristics, including ‘innovative leader in the industry,’ ‘treating employees with respect,’ ‘is socially responsible,’ ‘work culture values aligned’ and ‘leadership makes changes needed.’

The 20 companies with the best reputations as employers and the top three driving characteristics for each company, according to respondents in the 2019 survey undertaken for the Science/AAAS Custom Publishing Office. The companies without a 2018 rank did not receive enough mentions to qualify or did not receive a high enough ranking from the 2018 survey.

Innovation has been a leading driver of top employer status since the survey began in 2002, and this year was no exception. Other reasons for recognition as a top employer were treating employees with respect and having company values that align with theirs. Being socially responsible and having leadership that can make needed changes were also important characteristics of top companies, AAAS said.

The Science and Science Careers’ 2019 annual Top Employers Survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers in these industries as well as their driving characteristics. This year more than 7,500 people participated; and these respondents were from North America (72%), Europe (19%), Asia/Pacific Rim (7%), and other regions (2%); about 95% work in the biotechnology and pharmaceutical industry.

Survey responses were analyzed by The Brighton Consulting Group, which used a mathematical process to determine the driving characteristics of a top employer and to assign a unique score to rate each company’s employer reputation. Each company received a ranking, for example, on the basis of whether it treats its employees with respect, and whether its work culture values align with employees’ personal values.

About AAAS:
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journals Science; Science Advances, a digital, open-access journal; Science Immunology; Science Robotics; Science Signaling; and Science Translational Medicine. AAAS was founded in 1848 and includes nearly 250 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world. The nonprofit AAAS is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, public engagement, and more. For additional information about AAAS, see www.aaas.org.

About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It is a leading global player for APIs including statins, immunosuppressants and specialty molecules. Biocon has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the U.S. and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Biocon is committed to pursue the path of innovation to develop products that have the potential to benefit a billion lives. Biocon Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company has a large portfolio of biosimilars under global clinical development with three of these commercialized in developed markets like EU, Australia, U.S. and Japan.

<< Back

Download Press Release
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved